|
PDP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.51519999997052E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.2790999999911E-05 |
| Normal-vs-Stage2 |
4.420300E-03 |
| Normal-vs-Stage3 |
1.20140000003932E-06 |
| Normal-vs-Stage4 |
8.02250000000448E-05 |
| Stage1-vs-Stage2 |
7.739600E-01 |
| Stage1-vs-Stage3 |
5.407500E-02 |
| Stage1-vs-Stage4 |
3.576000E-01 |
| Stage2-vs-Stage3 |
1.187170E-01 |
| Stage2-vs-Stage4 |
3.325000E-01 |
| Stage3-vs-Stage4 |
6.844600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.75980000016729E-07 |
| Normal-vs-AfricanAmerican |
2.749800E-02 |
| Normal-vs-Asian |
1.063080E-03 |
| Caucasian-vs-AfricanAmerican |
4.043200E-01 |
| Caucasian-vs-Asian |
7.740800E-01 |
| AfricanAmerican-vs-Asian |
6.122800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.95810000000763E-06 |
| Normal-vs-Female |
1.04879999995866E-06 |
| Male-vs-Female |
5.758000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.37959999999493E-05 |
| Normal-vs-Age(41-60Yrs) |
2.58149999998736E-06 |
| Normal-vs-Age(61-80Yrs) |
1.58504999999698E-05 |
| Normal-vs-Age(81-100Yrs) |
1.386410E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.797600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.313400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.450000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.521800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.631000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.792200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.350900E-04 |
| Classical-VS-Follicular |
5.946300E-02 |
| Classical-VS-Other |
1.778390E-01 |
| Classical-VS-Normal |
6.39279999999909E-05 |
| Tall-VS-Follicular |
1.750830E-01 |
| Tall-VS-Other |
8.489000E-01 |
| Tall-VS-Normal |
1.9938999995528E-07 |
| Follicular-VS-Other |
4.856200E-01 |
| Follicular-VS-Normal |
4.95609999995317E-06 |
| Other-VS-Normal |
1.080420E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.84449999995895E-06 |
| Normal-vs-N1 |
5.53009999999521E-05 |
| N0-vs-N1 |
3.919600E-01 |
|
|
